Cargando…
Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy
The HIV infection is responsible for the most devastating global pandemic of the last century. More than 39 million people have died of HIV/AIDS since 1981. The development of the antiretroviral (ARV) treatment begins with the discovery of zidovudine a nucleoside reverse transcriptase inhibitor. Thi...
Autores principales: | Iacob, Simona A., Iacob, Diana G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711820/ https://www.ncbi.nlm.nih.gov/pubmed/29230203 http://dx.doi.org/10.3389/fmicb.2017.02323 |
Ejemplares similares
-
Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis
por: Iacob, Simona, et al.
Publicado: (2019) -
Intestinal Microbiota as a Host Defense Mechanism to Infectious Threats
por: Iacob, Simona, et al.
Publicado: (2019) -
Ibalizumab: First Global Approval
por: Markham, Anthony
Publicado: (2018) -
Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment—Clinical Points of View and Practical Considerations
por: Iacob, Simona A., et al.
Publicado: (2017) -
Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients – a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown
por: Iacob, Simona Alexandra, et al.
Publicado: (2022)